Ntt Life Science

What Ntt Life Science does

NTT Life Science operates as NTT Precision Medicine Co., Ltd. (NTTプレシジョンメディシン株式会社), a Tokyo-based precision medicine subsidiary of NTT Group established in 2019. The company integrates clinical records, examination data, genetic information, and insurance claims data to deliver personalized medicine and health management services across the Japanese market.

Its core offerings include the Genovision family of genetic testing services (base genetic analysis, Genovision Dock for personalized health strategies, and Genovision PGx for pharmacogenomics), the Japan Precision Medicine Platform (JPP) for integrated data collection, analysis, and utilization, the NTT Cohort service for working-population health analysis using genetic, examination, and receipt data, and Mobacal, a cloud-based electronic medical record (EMR) system with an AI-assisted documentation option launched in 2026. Adjacent revenue lines include corporate health management consulting, specific health guidance (metabolic/blood glucose focus), and workforce training programs covering mental skills, women's health literacy, physical fitness, and carbohydrate control.

NTT Precision Medicine sells primarily through direct enterprise engagement to hospitals, clinics, and corporate employers, with additional academic and municipal collaborations (e.g., Okayama University and Tamano City regional healthcare project). The company operates within a group structure that includes subsidiaries PRiME-R and Clinical Support Co., Ltd. Pricing is not publicly disclosed, no revenue figures are available, and no funding rounds appear in the source data, consistent with a captive NTT Group subsidiary.

Name

Ntt Life Science

Legal name

NTTプレシジョンメディシン株式会社

Website

https://ntt-lifescience.co.jp

Company type

Private

Founded year

2019

Operating status

Operating

Short description

NTT Precision Medicine is a Tokyo-based NTT Group subsidiary established in 2019 that provides precision medicine services in Japan, including genetic testing (Genovision), pharmacogenomics, the Japan Precision Medicine Platform, cloud EMR (Mobacal), and corporate health management for healthcare providers and employers.

Ownership category

akta.pro rank

Product category

Precision Medicine Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industry

Health Data, Vital Statistics & Population Health Informatics (BPAIAJAM)

Keywords

• Precision medicine services
• Genetic testing services
• Electronic medical records
• Health data analytics
• Pharmacogenomics testing

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels3 records

Core offering

NTT Life Science (operating as NTT Precision Medicine) provides precision medicine solutions built on the Japan Precision Medicine Platform (JPP), which integrates clinical, examination, genetic, and healthcare data. Its core offerings include the Genovision family of genomic testing services (including Genovision PGx for pharmacogenomics), the Mobacal cloud-based electronic medical record system, and NTT Cohort for population-level analysis of employed generations. The company also delivers corporate health management services, specific health guidance, consulting, and workplace training programs for healthcare providers, employers, and research institutions in Japan.

Product overview

NTT Precision Medicine Group operates a platform-plus-modules architecture centered on the Japan Precision Medicine Platform (JPP), which integrates clinical and healthcare data for precision medicine. The core product portfolio includes Genovision family (genomic analysis services comprising Genovision base service, Genovision Dock for health checkups, and Genovision PGx for pharmacogenomics), Mobacal electronic medical record system, and NTT Cohort for population health analysis. Supporting services include corporate health management consulting, specific health guidance, and various training programs (mental skills, women's health literacy, physical fitness, carbohydrate control). The platform emphasizes data-driven personalized healthcare combining genetic, examination, and medical record data.

Differentiator

Problem solved

Functional benefit

Brands

• Genovision（ゲノビジョン）: Precision medicine genetic testing and analysis platform for clinical and health management applications.
• Genovision PGx（ゲノビジョン ピージーエックス）
• Japan プレシジョン・メディシンプラットフォーム®（JPP）
• NTTコホート
• Mobakal（モバカル）/ Mobakal Hospital（モバカルホスピタル）
• Genovision Dock®（ゲノビジョン ドック）

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Four partnerships are on record, tiered minor.

• PRiME-R (プライム・アール)minorOthersGroup company within the NTT Precision Medicine Group, appears in website branding alongside other group companies. Nature of relationship is group company/affiliate rather than external partnership.
• 株式会社クリニカルサポート (Clinical Support Co., Ltd.)minorOthersGroup company within the NTT Precision Medicine Group. Affiliated company providing clinical support services, appears in website branding alongside other group companies.
• 岡山大学 (Okayama University)minorStrategic or Co-development PartnerAcademic partnership for precision medicine initiatives. NTT Precision Medicine collaborated with Okayama University and Tamano City on a project in Okayama Prefecture, presented at the 50th Annual Meeting of the Japanese Society for Genetic Counseling.
• 玉野市 (Tamano City)minorStrategic or Co-development PartnerMunicipal partnership for regional healthcare initiative. Collaboration with Okayama University and NTT Precision Medicine on a regional healthcare project in Tamano City, Okayama Prefecture.

Recent moves5 records

Expansion highlights5 records

Direct peers

• Foundation Medicine (Roche): Molecular diagnostics and comprehensive genomic profiling company for oncology. Directly comparable in clinical-grade genomic analysis and clinical-decision support, although focused on oncology rather than broad preventive genomics.
• 23andMe: Consumer-facing genetic testing and health-risk analytics platform. Comparable as a genetic-testing brand business, although operating primarily in the US/Canada rather than Japan; useful as a category benchmark for Genovision-style consumer testing.
• Myriad Genetics: US-based genetic testing company spanning hereditary cancer, pharmacogenomics, and broader germline testing. Directly comparable in clinical and PGx genetic testing, though operating in a different geography with broader US payor relationships.
• Genesis Healthcare Co., Ltd. Japanese genetic testing and personalized-medicine service provider. Directly comparable to NTT Precision Medicine as both operate Japan-based genetic testing services competing for the same healthcare-provider, consumer, and corporate-wellness customer base.
• Sophia Genetics: Data-driven precision medicine analytics platform for hospitals and labs, using multimodal clinical and genomic data. Directly comparable to NTT Precision Medicine's JPP/NTT Cohort analytics layer and shared focus on genomics-informatics for clinical decision support.

Emerging players

• Color Genomics: Genetic testing and population-genomics platform with employer, public-health, and clinical offerings. Partially comparable to NTT Precision Medicine's Genovision Dock and corporate wellness stack, though primarily US-focused.
• Personal Genome Diagnostics (Labcorp): Cancer genomics and molecular diagnostics services. Partially comparable to NTT Precision Medicine's clinical-grade genomic analysis capability, with overlap in clinical decision support but narrower in scope and disease focus.

Broad incumbents

• Sysmex Corporation: Japanese leader in in-vitro diagnostics and clinical laboratory solutions. A broader diagnostics incumbent with overlap in clinical lab and hospital workflows relevant to Mobacal's EMR and precision-medicine deployments.
• M3 Inc. Japanese healthcare platform spanning physician digital channels, clinical research, and data services. A broader incumbent in Japanese healthcare data and pharma services, competing for adjacent enterprise health-data budgets rather than direct genetic-testing customers.
• DeNA Co., Ltd. Japanese internet/tech company with healthcare and medical-data businesses. A broader incumbent in Japanese digital health, comparable for enterprise health-IT and consumer-health service distribution rather than core genetic-testing overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ntt Life Science